Clinical Trial Update: A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment [Phase 2]

View source ↗

Summary

PepGen's Phase 2 study of PGN-EDO51 for Duchenne Muscular Dystrophy amenable to exon 51 skipping has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• PGN-EDO51

Snippet

Sponsor: PepGen Inc | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: TERMINATED